131 related articles for article (PubMed ID: 31128516)
21. External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer.
Yang YJ; Lin GW; Li GX; Dai B; Ye DW; Wu JL; Xie HY; Zhu Y
Asian J Androl; 2018; 20(2):184-188. PubMed ID: 29111539
[TBL] [Abstract][Full Text] [Related]
22. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer.
Fan L; Wang Y; Chi C; Pan J; Xun S; Xin Z; Hu J; Zhou L; Dong B; Xue W
BJU Int; 2017 Aug; 120(2):226-232. PubMed ID: 28107595
[TBL] [Abstract][Full Text] [Related]
23. [Relationship of serum prostate-specific antigen and alkaline phosphatase levels with bone metastases in patients with prostate cancer].
Wang ZL; Wang XF
Zhonghua Nan Ke Xue; 2005 Nov; 11(11):825-7. PubMed ID: 16333960
[TBL] [Abstract][Full Text] [Related]
24. Prognostic models for predicting overall survival in metastatic castration-resistant prostate cancer: a systematic review.
Pinart M; Kunath F; Lieb V; Tsaur I; Wullich B; Schmidt S;
World J Urol; 2020 Mar; 38(3):613-635. PubMed ID: 30554274
[TBL] [Abstract][Full Text] [Related]
25. Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
Heck MM; Thaler MA; Schmid SC; Seitz AK; Tauber R; Kübler H; Maurer T; Thalgott M; Hatzichristodoulou G; Höppner M; Nawroth R; Luppa PB; Gschwend JE; Retz M
BJU Int; 2017 Jan; 119(1):30-37. PubMed ID: 27037533
[TBL] [Abstract][Full Text] [Related]
26. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
[TBL] [Abstract][Full Text] [Related]
27. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
Kosaka T; Hongo H; Oya M
BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the Prognostic Significance of Circulating Tumor DNA in Metastatic Castrate Resistant Prostate Cancer.
Shaya J; Nonato T; Cabal A; Randall JM; Millard F; Stewart T; McKay RR
Clin Genitourin Cancer; 2021 Dec; 19(6):564.e1-564.e10. PubMed ID: 34452870
[TBL] [Abstract][Full Text] [Related]
29. Eradication of BRAF K601E Mutation in Metastatic Castrate-resistant Prostate Cancer Treated With Cabazitaxel and Carboplatin: A Case Report.
Steinwald P; Ledet E; Sartor O
Clin Genitourin Cancer; 2020 Jun; 18(3):e312-e314. PubMed ID: 31917173
[No Abstract] [Full Text] [Related]
30. Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis.
Liu Y; Zhao S; Wang J; Zhu Z; Luo L; Li E; Tang F; Zhao Z
Urol Int; 2019; 102(4):373-384. PubMed ID: 30517936
[TBL] [Abstract][Full Text] [Related]
31. The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population.
Heller G; Fizazi K; McCormack R; Molina A; MacLean D; Webb IJ; Saad F; de Bono JS; Scher HI
Clin Cancer Res; 2017 Apr; 23(8):1967-1973. PubMed ID: 27678453
[No Abstract] [Full Text] [Related]
32. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
[TBL] [Abstract][Full Text] [Related]
33. [Biomarkers in metastatic castration-resistant prostate cancer].
Miller K
Aktuelle Urol; 2015 Jan; 46(1):66-70. PubMed ID: 25658233
[TBL] [Abstract][Full Text] [Related]
34. Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer.
Josefsson A; Linder A; Flondell Site D; Canesin G; Stiehm A; Anand A; Bjartell A; Damber JE; Welén K
Prostate; 2017 Jun; 77(8):849-858. PubMed ID: 28295408
[TBL] [Abstract][Full Text] [Related]
35. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer.
Moreira DM; Howard LE; Sourbeer KN; Amarasekara HS; Chow LC; Cockrell DC; Hanyok BT; Pratson CL; Aronson WJ; Kane CJ; Terris MK; Amling CL; Cooperberg MR; Liede A; Freedland SJ
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):333-7. PubMed ID: 26171882
[TBL] [Abstract][Full Text] [Related]
36. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
37. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.
Carles J; Castellano D; Méndez-Vidal MJ; Mellado B; Saez MI; González Del Alba A; Perez-Gracia JL; Jimenez J; Suárez C; Sepúlveda JM; Manneh R; Porras I; López C; Morales-Barrera R; Arranz JÁ
Clin Genitourin Cancer; 2018 Dec; 16(6):e1133-e1139. PubMed ID: 30104161
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer.
Miyake H; Matsushita Y; Watanabe H; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Anticancer Res; 2019 Mar; 39(3):1391-1396. PubMed ID: 30842173
[TBL] [Abstract][Full Text] [Related]
39. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
Fenioux C; Louvet C; Charton E; Rozet F; Ropert S; Prapotnich D; Barret E; Sanchez-Salas R; Mombet A; Cathala N; Joulia ML; Molitor JL; Henriques J; Bonnetain F; Cathelineau X; Bennamoun M
BJU Int; 2019 Feb; 123(2):300-306. PubMed ID: 30099821
[TBL] [Abstract][Full Text] [Related]
40. Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer.
Karzai FH; Madan RA; Figg WD
South Med J; 2015 Apr; 108(4):224-8. PubMed ID: 25871992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
